1. Quanterix approved RSU grants of 267,269 shares to 20 new employees. 2. Grants are linked to the acquisition of Akoya Biosciences. 3. RSUs will fully vest after one year of continued employment. 4. Quanterix specializes in ultra-sensitive biomarker detection technology. 5. The acquisition enhances capabilities in precision medicine and diagnostics.
The RSU grants indicate company growth and new talent acquisition, which can positively influence stock performance. Historically, employee incentives like RSUs have correlated with strengthened company morale and productivity, leading to better performance metrics.
The acquisition and RSU grants signal robust growth strategies, likely attracting investor interest. Employee motivation and specialized hiring can lead to better product innovation, influencing stock price positively.
The immediate hiring and RSU grants can boost employee motivation and productivity, reflecting positively within the next year. Long-term impact will depend on how effectively the integration with Akoya is executed.
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units (“RSUs”) representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual’s continued employment with the Company or one of its subsidiaries through the vesting date.
About Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics.
Learn more at www.quanterix.com.